TSHA (Taysha Gene Therapies Inc) רווח למניה לשנה מתגלגלת

The year-over-year EPS trend (trailing 12 months) demonstrates the impact of Fed policy on Taysha Gene Therapies (TSHA) capital, where -23.50 records the magnitude of this parameter. Taysha Gene Therapies (TSHA) develops gene therapy to combat Rett syndrome, relying on strict patent protection. The current startup operates on grants, burning cash without stable revenue. However, strong clinical data creates a powerful technological barrier against competitors.
Taysha Gene Therapies Inc - פילוחים אנליטיים ומדדי מפתח (TSHA)

An investment audit of Taysha Gene Therapies (TSHA) requires an analysis of earnings per share dynamics, where the calculation of annual EPS (TTM) changes reveals the business's ability to generate value under tight monetary policy. For a single-product structure with binary clinical trial risks, the history of YoY EPS (TTM) percentage changes serves as an indicator of financial resilience ahead of a potential compression of market multiples.